PERCEPTIVE INFORMATICS® DATALABS® EDC SOLUTION IMPLEMENTED BY 15 OF THE TOP GLOBAL BIOPHARMACEUTICAL COMPANIES
Boston, MA, December 19, 2011—Perceptive Informatics®, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that its DataLabs® Electronic Data Capture (EDC) solution has been implemented by 15 of the top 35 global biopharmaceutical companies. The award-winning solution has gained momentum with sponsors and clinical sites worldwide. This latest milestone was preceded by an independent report from Industry Standard Research, which ranked the DataLabs EDC solution the highest in overall satisfaction among EDC solutions in a survey of principal investigators and site coordinators.
“The DataLabs EDC solution has helped many biopharmaceutical sponsors, CROs, and clinical sites realize the true potential of EDC and its central role in enabling a more effective clinical development process. By really listening to customer needs, we have evolved the DataLabs EDC solution to incorporate greater usability, functionality, performance, and scalability capabilities. Sponsors are seeing the value of our EDC solution as an integral part of our eClinical Suite, which has been designed to help them accelerate development and achieve the next level of efficiency,” said Steve Kent, President, Perceptive Informatics.
According to Mr. Kent, “Superior user experiences have continued to fuel adoption. We are encouraged by the momentum that the DataLabs solution is experiencing in the market. This reinforces that Perceptive has an industry-leading EDC system.”
The DataLabs EDC solution has been developed to simplify workflows and streamline the process from study design to data collection, management, and reporting. Perceptive offers the DataLabs EDC solution as a software-as-a-service (SaaS) application, which is entirely hosted, maintained and supported by Perceptive’s quality-assured eClinical platform.
Features of the DataLabs 5.0 EDC solution include a user-friendly interface, a powerful reporting engine, web-based study design tool and sophisticated search function, as well as advanced export functionality to easily extract EDC data. The solution has a web-based application programming interface (API) to enable seamless integration among multiple applications. With a single electronic clinical data management platform to unify the functionality of paper data entry with the flexibility of EDC, the system provides sponsors with the flexibility to choose their preferred method of data collection.
In addition to the DataLabs EDC solution, the comprehensive eClinical portfolio from Perceptive Informatics includes Randomization and Trial Supply Management (RTSM) technologies, Clinical Trial Management Systems (CTMS), and Medical Imaging as well as Electronic Patient Reported Outcomes (ePRO). The Perceptive eClinical Suite provides convergence among systems for real-time data interchange and enables diverse applications to work synergistically.
For more information about Perceptive’s DataLabs EDC solution visit: http://www.perceptive.com/edc/.
# # #
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged